[1]姜琳,袁晋青.缺血性心肌病的血运重建治疗[J].心血管病学进展,2015,(6):677-681.[doi:10.3969/j.issn.1004-3934.2015.06.006]
 JIANG Lin,YUAN Jinqing.Revascularization in Ischemic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2015,(6):677-681.[doi:10.3969/j.issn.1004-3934.2015.06.006]
点击复制

缺血性心肌病的血运重建治疗()
分享到:

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2015年6期
页码:
677-681
栏目:
综述
出版日期:
2016-06-20

文章信息/Info

Title:
Revascularization in Ischemic Cardiomyopathy
作者:
姜琳袁晋青
北京协和医学院 中国医学科学院 国家心血管病中心 阜外医院心血管内科,北京 100037
Author(s):
JIANG Lin YUAN Jinqing
Department of Cardiology,Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100037, China
关键词:
缺血性心肌病 心力衰竭 血运重建
Keywords:
ischemic cardiomyopathy heart failure revascularization
分类号:
R541.2
DOI:
10.3969/j.issn.1004-3934.2015.06.006
文献标志码:
A
摘要:
缺血性心肌病是导致心力衰竭常见的原因。通过早期血运重建挽救冬眠心肌,可能在阻止和逆转心室重塑方面起到决定性作用。然而,由于缺血性心肌病患者的心功能严重受损,且冠状动脉病变往往较复杂,因此行血运重建的风险较高。目前关于血运重建能否改善心力衰竭患者的预后仍存争议。现阐述缺血性心肌病患者血运重建治疗的研究进展。
Abstract:
Ischemic cardiomyopathy is the most common cause of heart failure. Early revascularization of viable myocardium may play a critical role in preventing and reversing ventricular remodeling. However, there is an increased risk of morbidity related to the revascularization procedure in patients with ischemic cardiomyopathy due to severely impaired cardiac function and complex coronary lesions. The role of coronary revascularization in improving heart failure associated morbidity and mortality remains controversial. In this review, the research progression of revascularization in ischemic cardiomyopathy is discussed.

参考文献/References:

[1] Felker GM, Shaw LK, O'Connor CM. A standardized definition of ischemic cardiomyopathy for use in clinical research[J]. J Am Coll Cardiol, 2002,39:210-218.
[2] Gheorghiade M, Sopko G, de Luca L, et al. Navigating the crossroads of coronary artery disease and heart failure[J]. Circulation,2006,114:1202-1213.
[3] 中华医学会心血管病学分会.中国部分地区1980、1990、2000年慢性心力衰竭住院病例回顾性调查[J]. 中华心血管病杂志,2002,30:450-454.
[4] Suleiman M, Khatib R, Agmon Y, et al. Early inflammation and risk of long-term development of heart failure and mortality in survivors of acute myocardial infarction predictive role of C-reactive protein[J]. J Am Coll Cardiol,2006,47:962-968.
[5] Hellermann JP, Jacobsen SJ, Redfield MM, et al. Heart failure after myocardial infarction:clinical presentation and survival[J]. Eur J Heart Fail,2005,7:119-125.
[6] Sardi GL, Gaglia MA Jr,Maluenda G, et al. Outcome of percutaneous coronary intervention utilizing drug-eluting stents in patients with reduced left ventricular ejection fraction[J]. Am J Cardiol,2012,109:344-351.
[7] Al-Mohammad A, Walton MS. Prevalence of myocardial viability as detected by positron emission tomography in patients with ischemic cardiomyopathy[J]. Circulation,2000,102:E31.
[8] Schinkel AF, Bax JJ, Sozzi FB, et al. Prevalence of myocardial viability assessed by single photon emission computed tomography in patients with chronic ischemic left ventricular dysfunction[J]. Heart,2002,88:125-130.
[9] Patel MR, Dehmer GJ, Hirshfeld JW, et al. ACCF/SCAI/STS/AATS/AHA/ASNC/HFSA/SCCT 2012 appropriate use criteria for coronary revascularization focused update[J]. J Am Coll Cardiol,2012,59:857-881.
[10] Patel MR, White RD, Abbara S, et al. 2013 ACCF/ACR/ASE/ASNC/SCCT/SCMR appropriate utilization of cardiovascular imaging in heart failure[J]. J Am Coll Cardiol,2013,61:2207-2231.
[11] Allman KC, Shaw LJ, Hachamovitch R, et al. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis[J]. J Am Coll Cardiol,2002,39:1151-1158.
[12] Bax JJ, Poldermans D, Elhendy A, et al. Improvement of left ventricular ejection fraction, heart failure symptoms and prognosis after revascularization in patients with chronic coronary artery disease and viable myocardium detected by dobutamine stress echocardiography[J]. J Am Coll Cardiol,1999,34:163-169.
[13] Bonow RO, Maurer G, Lee KL, et al. Myocardial viability and survival in ischemic left ventricular dysfunction[J]. N Engl J Med,2011,364:1617-1625.
[14] Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS guidelines on myocardial revascularization[J]. Eur Heart J,2014,35:2541-2619.
[15] Chareonthaitawee P, Gersh BJ, Araoz PA, et al. Revascularization in severe left ventricular dysfunction: the role of viability testing[J]. J Am Coll Cardiol,2005,46:567-574.
[16] Gerber BL, Rousseau MF, Ahn SA, et al. Prognostic value of myocardial viability by delayed-enhanced magnetic resonance in patients with coronary artery disease and low ejection fraction:impact of revascularization therapy[J]. J Am Coll Cardiol,2012,59:825-835.
[17] Bax JJ, van der Wall EE, Harbinson M. Radionuclide techniques for the assessment of myocardial viability and hibernation[J]. Heart,2004,90(Suppl 5):v26-v33.
[18] Velazquez EJ, Lee KL, Deja MA, et al. Coronary-artery bypass surgery in patients with left ventricular dysfunction[J]. N Engl J Med,2011,364:1607-1616.
[19] Yau TM, Fedak PW, Weisel RD, et al. Predictors of operative risk for coronary bypass operations in patients with left ventricular dysfunction[J]. J Thorac Cardiovasc Surg,1999,118:1006-1013.
[20] Estafanous FG, Loop FD, Higgins TL, et al. Increased risk and decreased morbidity of coronary artery bypass grafting between 1986 and 1994[J]. Ann Thorac Surg,1998,65:383-389.
[21] Sedlis SP, Ramanathan KB, Morrison DA, et al. Outcome of percutaneous coronary intervention versus coronary bypass grafting for patients with low left ventricular ejection fractions, unstable angina pectoris, and risk factors for adverse outcomes with bypass(the AWESOME Randomized Trial and Registry)[J]. Am J Cardiol,2004,94(1):118-120.
[22] Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure[J]. J Am Coll Cardiol,2013,62:e147-e239.
[23] 中华医学会心血管病学分会.中国心力衰竭诊断和治疗指南2014[J]. 中华心血管病杂志,2014,42:98-122.

相似文献/References:

[1]赵诚,综述,朱丹,等.甲状旁腺功能减退与心脏损害[J].心血管病学进展,2016,(2):133.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.009]
 ZHAO Cheng,ZHU Dan.Hypoparathyroid and Cardiac Damage[J].Advances in Cardiovascular Diseases,2016,(6):133.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.009]
[2]王振,综述,惠杰,等.迷走神经刺激与心力衰竭[J].心血管病学进展,2016,(2):197.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.026]
 WANG Zhen,HUI Jie.Vagus Nerve Stimulation and Heart Failure[J].Advances in Cardiovascular Diseases,2016,(6):197.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.026]
[3]陈焕,综述,邓平,等.S100A1蛋白基因治疗心力衰竭的研究进展[J].心血管病学进展,2016,(3):302.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.023]
 CHEN Huan,DENG Ping.Research Progress in S100A1 Gene Therapy for Heart Failure[J].Advances in Cardiovascular Diseases,2016,(6):302.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.023]
[4]唐毅,柳志红,黄智伟,等.运动振荡呼吸在心力衰竭中的应用[J].心血管病学进展,2015,(5):551.[doi:10.3969/j.issn.1004-3934.2015.05.007]
 TANG Yi,LIU Zhihong,HUANG Zhiwei,et al.Application of Exercise Oscillatory Ventilation in Heart Failure[J].Advances in Cardiovascular Diseases,2015,(6):551.[doi:10.3969/j.issn.1004-3934.2015.05.007]
[5]梅宝菲,孔一慧,李为民.睡眠障碍与心血管疾病研究新进展[J].心血管病学进展,2015,(5):603.[doi:10.3969/j.issn.1004-3934.2015.05.020]
 MEI Baofei,KONG Yihui,LI Weimin.Relationship Between Somnipathy and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2015,(6):603.[doi:10.3969/j.issn.1004-3934.2015.05.020]
[6]唐光能,洪炳哲.Junctate蛋白在心力衰竭中的研究进展[J].心血管病学进展,2015,(5):629.[doi:10.3969/j.issn.1004-3934.2015.05.028]
 TANG Guangneng,HONG Bingzhe.Research Development of Junctate Protein in Heart Failure[J].Advances in Cardiovascular Diseases,2015,(6):629.[doi:10.3969/j.issn.1004-3934.2015.05.028]
[7]崔圆,孙宏超,侯维娜,等.生长分化因子15与心力衰竭的相关研究进展[J].心血管病学进展,2015,(6):759.[doi:10.3969/j.issn.1004-3934.2015.06.026]
 CUI Yuan,SUN Hongchao,HOU Weina,et al.Research Progress on Growth Differentiation Factor-15 Associated with Heart Failure[J].Advances in Cardiovascular Diseases,2015,(6):759.[doi:10.3969/j.issn.1004-3934.2015.06.026]
[8]秦莉 张艺文 杨晓倩 王燕凤 汪汉.系统性红斑狼疮合并心力衰竭的发病机制及病因[J].心血管病学进展,2020,(4):381.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.013]
 QIN Li,ZHANG Yiwen,YANG Xiaoqian,et al.The Pathogenesis and Etiology of Heart Failure in Systemic lupus Erythematosus[J].Advances in Cardiovascular Diseases,2020,(6):381.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.013]

备注/Memo

备注/Memo:
基金项目:国家“十二五”科技支撑计划(2011BAI11B07) 作者简介:姜琳(1987—),主治医师,硕士,主要从事冠心病研究。Email:jianglin27@163.com 通信作者:袁晋青(1962—), 主任医师,博士,主要从事冠心病研究。Email:jqyuan29007@sina.com
更新日期/Last Update: 2016-06-20